Histone Deacetylase Inhibitors Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Histone Deacetylase Inhibitors Market: By Drug Class (Class I, Class II, Class III, Class IV), By Application (Neurology, Oncology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Latin America, Europe, Middle East and Africa, Asia Pacific)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Histone Deacetylase Inhibitors Market is expected to grow at a CAGR of xx% during 2021 to 2027. Histone deacetylase inhibitors are the products involved in inhibition of histone deacetylase, which removes acetyl groups from N-acetyl lysine amino acid present on the histone, and allows the histones to wrap DNA more tightly. Histone deacetylase inhibitors are used in the neurology and psychiatry as anti-epileptics and mood stabilizers. Moreover, these are also used in the treatment of cancer, parasitic, and inflammatory diseases. Histone deacetylase (HDAC) is an enzyme that inhibits histone deacetylase by eliminating the scetyl group from the amino acid n-acetyl lysine. Histone deacetylase inhibitors are showing promise as a tool for cancer diagnosis, treatment, and prognosis. It’s also used to treat haematological malignancies and plays a vital function in epigenetic and non-epigenetic regulation. Because of the rising incidence of various types of cancer and the growing need for improved cancer detection and therapies, the global histone deacetylase inhibitors market is booming. Furthermore, one of the primary drivers of market expansion is an increase in R&D activities for cancer therapy and other neurological disorders. However, restrictive reimbursement regulations and HDAC inhibitor uncertainty may limit market expansion to some extent. Several histone deacetylase inhibitor compounds have been tested in clinical trials for various cancers in recent years. The chemical structure of these inhibitors is used to classify them. Hydroxamic acid-based drugs are the most extensively studied class of histone deacetylase inhibitors.

Histone Deacetylase Inhibitors Market

MARKET SUMMARY
-
xx% CAGR
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– xx%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Histone Deacetylase Inhibitors Market

  • The report on global Histone Deacetylase Inhibitors Market gives historical, current, and future market sizes (US$ Bn) on the basis of drug class, application, distribution channel and geography.
  • Histone Deacetylase Inhibitors Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Novartis AG (Switzerland)
  • AstraZeneca Plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Celgene Corporation (U.S.)
  • Eisai Co. Ltd. (Japan)
Dynamics

Histone Deacetylase Inhibitors Market

Rise in prevalence of cancers and neurological disorders drives the market. Moreover, increase in the R&D activities for the cancer treatment and other diseases, rise in demand to improve effectiveness of newer treatment therapies, and promising pipeline drugs, are anticipated to fuel the market. However, lack of favorable reimbursement policies and uncertainty issues and stringent regulations for the product approval are restraining the growth of histone deacetylase inhibitors market over the forecast years.


North-America got significant share

Histone Deacetylase Inhibitors Market

Geographically, global histone deacetylase inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America histone deacetylase inhibitors marketis poised to grow at notable CAGR owing to increase in R&D for the development of newer drugs, rise in prevalence of cancer and neurological disorders, and high acceptance of HDAC products are expected to the boost the market. Europe histone deacetylase inhibitors market is rising due to increase in the aging population results to rise in prevalence of neurological disorders, grow in demand for advanced treatments, and pipeline drugs under the various stages of clinical trials are bolster the market. However, Asia Pacific histone deacetylase inhibitors market is poised to grow due to entry of market players into Asia Pacific countries with launch of newer products, rise in medical tourism for cancer treatment in Asia Pacific countries, and large patient pool are expected to offer healthy growth opportunities for the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report covers exhaustive regional information, that includes North America, Asia-Pacific, Latin America and Middle East and Africa.
  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Histone Deacetylase Inhibitors Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Novartis AG (Switzerland)
  • AstraZeneca Plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Celgene Corporation (U.S.)
  • Eisai Co. Ltd. (Japan)
  • Merck & Co., Inc. (U.S.)
  • Acetylon Pharmaceuticals, Inc. (U.S.)
  • Celleron Therapeutics Ltd. (U.K.)
  • Innovation Pharmaceuticals, Inc. (U.S.)
  • Ranedis Pharmaceuticals (U.S.)

Description

Histone Deacetylase Inhibitors Market is expected to grow at a CAGR of xx% during 2021 to 2027. Histone deacetylase inhibitors are the products involved in inhibition of histone deacetylase, which removes acetyl groups from N-acetyl lysine amino acid present on the histone, and allows the histones to wrap DNA more tightly. Histone deacetylase inhibitors are used in the neurology and psychiatry as anti-epileptics and mood stabilizers. Moreover, these are also used in the treatment of cancer, parasitic, and inflammatory diseases. Histone deacetylase (HDAC) is an enzyme that inhibits histone deacetylase by eliminating the scetyl group from the amino acid n-acetyl lysine. Histone deacetylase inhibitors are showing promise as a tool for cancer diagnosis, treatment, and prognosis. It’s also used to treat haematological malignancies and plays a vital function in epigenetic and non-epigenetic regulation. Because of the rising incidence of various types of cancer and the growing need for improved cancer detection and therapies, the global histone deacetylase inhibitors market is booming. Furthermore, one of the primary drivers of market expansion is an increase in R&D activities for cancer therapy and other neurological disorders. However, restrictive reimbursement regulations and HDAC inhibitor uncertainty may limit market expansion to some extent. Several histone deacetylase inhibitor compounds have been tested in clinical trials for various cancers in recent years. The chemical structure of these inhibitors is used to classify them. Hydroxamic acid-based drugs are the most extensively studied class of histone deacetylase inhibitors.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX